GLP-1 Medications During Pregnancy & Breastfeeding: The Safety Guide
Medically Reviewed by
Board Certified Endocrinologist
Published
Mar 18, 2026
Last Reviewed
Mar 18, 2026
Sources
5 peer-reviewed
Standard
YMYL / E-E-A-T
Key Takeaways
- •GLP-1 medications must be stopped before trying to conceive — at least 2 months before (semaglutide) due to long half-life.
- •Animal studies show potential fetal harm at high doses; human pregnancy data is limited but concerning enough to contraindicate use.
- •Accidental first-trimester exposure requires immediate consultation with your OB/GYN — the risk to the pregnancy needs to be assessed individually.
- •GLP-1 medications are not recommended during breastfeeding; it is unknown whether they pass into breast milk.
- •Women with obesity or PCOS often experience improved fertility on GLP-1 therapy — unintended pregnancy risk is real.
Why GLP-1 Medications Are Contraindicated in Pregnancy
All FDA-approved GLP-1 receptor agonists carry a contraindication for use during pregnancy. This is primarily based on animal reproductive studies showing adverse fetal outcomes — including reduced fetal growth, skeletal abnormalities, and increased fetal death — at doses producing drug exposures similar to those in humans at clinical doses. Human data is extremely limited because pregnant women are excluded from clinical trials, and the drugs are not prescribed during pregnancy. The mechanism of potential harm is not fully understood, but GLP-1 receptors are expressed in placental tissue, suggesting the drug may directly affect fetal development. Until robust human safety data exists, the risk-benefit calculation does not support use during pregnancy.
When to Stop GLP-1 Medications Before Trying to Conceive
The timing depends on which medication you take, because half-lives differ significantly. Semaglutide (Wegovy, Ozempic) has the longest half-life of approximately one week — but to achieve 95% elimination, you need approximately 5 half-lives, meaning the drug takes about 5 weeks to substantially clear. The FDA label for Wegovy recommends stopping at least 2 months before a planned pregnancy. This conservative 2-month window accounts for variable elimination and the time needed for ovulatory cycles to normalize after weight loss. Tirzepatide (Zepbound, Mounjaro) has a similar half-life of about 5 days — also requiring approximately 2 months of washout. Liraglutide (Saxenda) has a shorter half-life of 13 hours and clears much faster, typically within 2–3 days. Dulaglutide (Trulicity) has a half-life of approximately 5 days. Regardless of which drug you take, the standard clinical recommendation is to stop at least 2 months before attempting conception.
What If You Become Pregnant While on a GLP-1?
Accidental pregnancy while on a GLP-1 medication does occur — particularly in women with PCOS or obesity whose fertility improves on treatment. If you discover you are pregnant while taking a GLP-1 medication: stop the medication immediately. Contact your OB/GYN or reproductive specialist as soon as possible. Report the exposure through your prescriber or directly to the manufacturer's pregnancy registry (both Novo Nordisk and Eli Lilly maintain registries). Do not panic — the absolute risk from early first-trimester exposure in humans is unknown, and animal studies use doses proportionally higher than typical human exposures. Your physician will assess the specific timing, dose, and duration of exposure to counsel you on the individual risk to your pregnancy.
GLP-1 Medications Can Improve Fertility in PCOS
This is critically important information for women of childbearing age. Obesity and PCOS (polycystic ovary syndrome) both cause anovulation — irregular or absent ovulation — which many women have lived with for years, assuming pregnancy is unlikely. GLP-1 medications improve insulin sensitivity and reduce androgen levels, directly restoring ovulatory cycles in many women with PCOS. Clinical studies show that semaglutide treatment significantly improves menstrual regularity and fertility markers in PCOS patients. Women who have been infertile or subfertile for years may find their fertility restored — sometimes before they realize it. This means reliable contraception is essential if you are sexually active and not trying to conceive, from the moment you begin GLP-1 therapy.
GLP-1 Medications and Breastfeeding
All current GLP-1 medications — semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide — are contraindicated or not recommended during breastfeeding. The primary reason: it is unknown whether these drugs are excreted in human breast milk. Animal studies show that semaglutide is excreted in rat milk. Given that GLP-1 receptors are expressed in developing tissues, potential exposure in nursing infants raises concern. The risk-benefit assessment does not support using GLP-1 medications while breastfeeding, particularly given that weight loss is not typically a medical emergency that cannot wait until after breastfeeding is complete. Discuss with your OB/GYN when it is appropriate to restart GLP-1 therapy after breastfeeding.
Returning to GLP-1 Therapy After Delivery or Weaning
Many women who used GLP-1 medications before pregnancy will want to restart them postpartum — either for obesity management, PCOS treatment, or other indications. After delivery (if not breastfeeding), most obesity medicine specialists recommend waiting until 6 weeks postpartum before restarting GLP-1 therapy to allow physiological stabilization and to confirm there are no postpartum complications. After weaning from breastfeeding, the clearance time is minimal for most GLP-1 drugs (1–2 weeks for semaglutide, shorter for others). GLP-1 medications can be restarted at the original starting dose and re-titrated — the same protocol as a new patient. Your previous response to the drug does not guarantee the same response postpartum, but most patients re-lose significant weight.
Frequently Asked Questions
These answers are for informational purposes only. Always consult your physician for personalized medical advice.
Was this article helpful?
Scientific References & Further Reading
- Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021.
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022.
- FDA Drug Approvals Database — GLP-1 Receptor Agonists. U.S. Food & Drug Administration.
- PubMed — GLP-1 Receptor Agonist Research Index. National Library of Medicine.
- Mayo Clinic — Semaglutide (GLP-1 Agonist): Uses, Side Effects, and Dosing. Mayo Clinic Drug Reference.
This content is produced in accordance with GLP-1 Health's editorial standards and is based on peer-reviewed clinical evidence from the sources cited above. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.
